Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-19.18 Insider Own2.28% Shs Outstand2.10M Perf Week9.91%
Market Cap5.35M Forward P/E- EPS next Y-2.71 Insider Trans0.00% Shs Float2.05M Perf Month14.90%
Income-27.63M PEG- EPS next Q-3.69 Inst Own6.84% Short Float2.44% Perf Quarter-42.05%
Sales0.00M P/S- EPS this Y74.73% Inst Trans27.89% Short Ratio0.94 Perf Half Y-75.48%
Book/sh4.55 P/B0.56 EPS next Y52.46% ROA-153.97% Short Interest0.05M Perf Year-91.74%
Cash/sh3.91 P/C0.65 EPS next 5Y- ROE-202.83% 52W Range2.09 - 42.40 Perf YTD-72.28%
Dividend Est.- P/FCF- EPS past 5Y8.89% ROI-315.49% 52W High-93.99% Beta-0.60
Dividend TTM- Quick Ratio2.42 Sales past 5Y0.00% Gross Margin- 52W Low22.01% ATR (14)0.28
Dividend Ex-Date- Current Ratio2.42 EPS Y/Y TTM14.61% Oper. Margin0.00% RSI (14)49.94 Volatility13.35% 11.27%
Employees26 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q50.43% Payout- Rel Volume0.42 Prev Close2.42
Sales Surprise- EPS Surprise6.20% Sales Q/Q- Earnings- Avg Volume53.16K Price2.55
SMA208.92% SMA50-10.79% SMA200-74.34% Trades Volume22,462 Change5.37%
Date Action Analyst Rating Change Price Target Change
Jan-26-21Initiated National Securities Buy $7
Apr-29-19Initiated Noble Capital Markets Outperform $5
May-15-24 04:42AM
May-14-24 08:31AM
May-13-24 08:31AM
May-08-24 06:08PM
May-07-24 09:15AM
08:31AM Loading…
May-01-24 08:31AM
Apr-09-24 08:31AM
Apr-04-24 08:57AM
Apr-03-24 08:31AM
Apr-02-24 08:31AM
Mar-22-24 04:10PM
Mar-19-24 01:24PM
Mar-12-24 09:01AM
Mar-06-24 08:30AM
Feb-07-24 08:15AM
07:30AM Loading…
Feb-06-24 07:30AM
Feb-05-24 07:30AM
Jan-31-24 08:42AM
Jan-05-24 07:00AM
Nov-23-23 08:30AM
Nov-03-23 09:00AM
Nov-01-23 07:30AM
Oct-20-23 03:00PM
Oct-06-23 09:00AM
Oct-04-23 12:00PM
Sep-21-23 08:30AM
Sep-19-23 09:00AM
Sep-08-23 08:00PM
Sep-07-23 07:30AM
12:00PM Loading…
Sep-04-23 12:00PM
Sep-01-23 09:20PM
Aug-31-23 12:44AM
Aug-24-23 12:25AM
Aug-23-23 02:06AM
Aug-22-23 07:30AM
Aug-13-23 10:24AM
Aug-10-23 07:30AM
Aug-08-23 01:04AM
Jul-28-23 08:00PM
Jul-25-23 01:22AM
Jul-21-23 04:15PM
Jul-20-23 01:05AM
Jul-19-23 08:00AM
Jul-18-23 08:37AM
Jul-12-23 01:00AM
Jul-07-23 09:00PM
Jul-06-23 08:17AM
Jul-05-23 08:35AM
Jun-29-23 09:03PM
Jun-28-23 08:35AM
Jun-02-23 10:15AM
Jun-01-23 11:59AM
May-31-23 12:59AM
May-30-23 07:30AM
May-26-23 06:00PM
May-25-23 05:00PM
May-23-23 07:30AM
May-09-23 07:15AM
May-08-23 07:30AM
May-02-23 03:30PM
Apr-19-23 09:11AM
Apr-18-23 09:11AM
Apr-03-23 06:12AM
Mar-23-23 07:30AM
Mar-13-23 07:30AM
Mar-08-23 07:30AM
Feb-27-23 08:30AM
Feb-23-23 07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Dec-15-22 07:00AM
Dec-14-22 07:00AM
Dec-02-22 08:15AM
Oct-24-22 09:45AM
Oct-07-22 07:45AM
Sep-08-22 08:15AM
Aug-16-22 07:00AM
Aug-15-22 07:00AM
Jul-13-22 07:00AM
Jun-02-22 07:00AM
May-19-22 08:15AM
May-17-22 08:23AM
May-09-22 08:15AM
May-05-22 08:30AM
Apr-18-22 08:15AM
Mar-31-22 07:05AM
Mar-23-22 08:00AM
Mar-14-22 04:48AM
Mar-02-22 08:00AM
Feb-15-22 09:00AM
Feb-09-22 08:15AM
Jan-31-22 12:04PM
Jan-27-22 11:23AM
Jan-24-22 07:09AM
Jan-10-22 09:17AM
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.